CrowdStrike Reports Mixed Financial Results And Weak Guidance
The stock of CrowdStrike Holdings (CRWD) is down 7% after the cybersecurity firm reported mixed quarterly financial results and issued disappointing forward guidance.The Austin, Texas-based company announced earnings per share (EPS) of $0.73 U.S., which was ahead of Wall Street’s consensus forecast of $0.66 U.S. Revenue for the quarter totaled $1.10 billion U.S., which was below consensus expectations of $1.11 billion U.S. Sales were up 20% from a year earlier.CrowdStrike’s forward guidance also came up short. The company guided for revenue in the current second quarter of $1.15 billion U.S. at the midpoint of its range. That was below analyst expectations that called for $1.16 billion U.S. in sales. The company maintained its full-year revenue outlook, but Wall Street expected the company to raise it. In its earnings release, CrowdStrike said higher interest rates and stubborn inflation have led its clients to cut their technology spending, weighing on demand for its cybersecurity products. Still, CrowdStrike’s management team said there has never been a greater need for cybersecurity given rising threats and ransomware attacks.CrowdStrike also faces growing competition from other cybersecurity firms such as Palo Alto Networks (PANW) and Fortinet (FTNT), among others. In May of this year, CrowdStrike cut 5% of its global workforce, saying it needed to adjust to slowing growth. Despite the slowdown in its business, the stock of CrowdStrike has risen 41% this year, and, prior to today, was trading at $488.76 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


